NORML Says DEA’s Newly Proposed Bulk Cultivation Rules Are “Unduly Onerous, Expensive, and Impractical”
NORML
MARCH 26, 2020
For the second time in four years, the US Drug Enforcement Administration is proposing regulatory changes to procedures governing the federally licensed manufacture of cannabis for clinical research purposes. Those entities who wish to either cultivate low-THC crops (those containing no more than 0.3
Let's personalize your content